Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain ...

Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...

A $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing.A $15 million standby equity ...

The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission ...

"cke_bm_3358S" style="display:none This outcome demonstrates the effectiv eness of the robotic approach in reducing pain, ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Nina Balanchivadze, MD, FACP, discusses how inclusive research begins at the community level by addressing barriers to trial ...